Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor (vol 76, pg 89, 2013)

被引：3
|
作者：
Kubitza, D.
Roth, A.
Becka, M.
Alatrach, A.
Halabi, A.
Hinrichsen, H.
Mueck, W.
机构：
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2013年 / 76卷 / 03期
关键词：
D O I：
10.1111/bcp.12215
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：489 / 489
页数：1
相关论文
共 50 条
  • [21] PHARMACOKINETICS, PHARMACODYNAMICS OF BI 11634, A DIRECT ORAL FACTOR XA INHIBITOR, AFTER MULTIPLE ORAL ADMINISTRATIONS.
    Huang, Fenglei
    Formella, Stephan
    Schepers, Cornelia
    Rubano, Vanessa
    Breithaupt-Groegler, Kerstin
    Castles, Mark A.
    Vyrill, Moulin
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (09): : 1061 - 1061
  • [22] EFFECT OF LOW- DOSE ASPIRIN ON THE PHARMACOKINETICS ( PK) AND PHARMACODYNAMICS ( PD) OF EDOXABAN, AN ORAL FACTOR Xa INHIBITOR.
    Mendell-Harary, J.
    Lee, F.
    Chen, S.
    Petrushun, V.
    He, L.
    Shi, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S63 - S63
  • [23] Apixaban, a direct factor Xa lnhibitor: Single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation
    Frosi, C.
    Yu, Z.
    Nepal, S.
    Bragat, A.
    Moore, K.
    Shenker, A.
    Barret, Y.
    Lacreta, F.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1132 - 1132
  • [24] Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment
    Stangier, Joachim
    Staehle, Hildegard
    Rathgen, Karin
    Roth, Willy
    Shakeri-Nejad, Kasra
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (12): : 1411 - 1419
  • [25] Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment
    Graff, Jochen
    Harder, Sebastian
    CLINICAL PHARMACOKINETICS, 2013, 52 (04) : 243 - 254
  • [26] Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
    Frost, Charles E.
    Byon, Wonkyung
    Song, Yan
    Wang, Jessie
    Schuster, Alan E.
    Boyd, Rebecca A.
    Zhang, Donglu
    Yu, Zhigang
    Dias, Clapton
    Shenker, Andrew
    LaCreta, Frank
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 79 (05) : 838 - 846
  • [27] Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers
    Huang, H. -L. A.
    Vaidyanathan, S.
    Yeh, C. -M.
    BiZot, M. -N.
    Dieterich, H. A.
    Dole, W. P.
    Howard, D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (09) : 2449 - 2456
  • [28] Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment
    Jochen Graff
    Sebastian Harder
    Clinical Pharmacokinetics, 2013, 52 : 243 - 254
  • [29] POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF PD 0348292, AN ORAL, DIRECT FACTOR XA INHIBITOR, IN HEALTHY SUBJECTS.
    Xuan, D.
    Boyd, R.
    DiCarlo, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S54 - S55
  • [30] Safety, Pharmacokinetics, and Pharmacodynamics of PD 0348292, an Oral, Direct Factor Xa Inhibitor, After Single and Multiple Dosings in Healthy Subjects
    Xuan, Dawei
    McBride, Scott
    Wastall, Philip
    Porcari, Anthony
    DiCarlo, Lorenzo
    Boyd, Rebecca A.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2016, 5 (01): : 13 - 26
12345